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TO THE EDITOR
In the June 2006 issue of the Journal,
Irvine and McLean comment on the
role of filaggrin gene (FLG) mutations in
atopic dermatitis (AD) and speculate
that a heritable barrier defect might also
play a role in psoriasis, being a disorder
with altered keratinization and sharing
genetic linkage regions with AD (Irvine
and McLean, 2006).
Psoriasis is a chronic inflammatory
skin disease with a strong genetic
background (Elder et al., 2001; Capon
et al., 2004). The predominant psoriasis
susceptibility locus PSORS1 in the
major histocompatibility complex re-
gion on human chromosome 6p21.3 is
found in different populations (Trem-
bath et al., 1997a; Jenisch et al., 1998;
Veal et al., 2001; Zhang et al., 2003),
and recently HLA Cw6 has been con-
firmed as the major disease-causing
gene in psoriasis (Nair et al., 2006).
However, HLA Cw6 might only
account for 35% of the genetic liability
to psoriasis (Trembath et al., 1997b)
and several additional gene loci have
been identified by linkage analysis
(Elder et al., 2001; Consortium, 2003;
Capon et al., 2004; Bowcock, 2005).
Some of these gene loci are shared with
other inflammatory disorders, for in-
stance with Crohn’s disease on chro-
mosome 16 (Jenisch et al., 2006), or
with atopic eczema on chromosomes
1q21, 17q25, 3q21, and 20p (Cookson
et al., 2001).
Recently, two loss-of-function muta-
tions in the FLG gene (R501X and
2282del4) residing in the so-called
epidermal differentiation complex on
chromosome 1q21 have been demon-
strated to cause ichthyosis vulgaris
(Smith et al., 2006), and in a subse-
quent study to account significantly for
the genetic susceptibility to AD, (Pal-
mer et al., 2006) a finding which has
meanwhile been confirmed by several
other groups (Barker et al., 2007;
Marenholz et al., 2006; Ruether et al.,
2006; Sandilands et al., 2006; Stemmler
et al., 2007; Weidinger et al., 2006).
FLG is involved in the formation
of the stratum corneum and homozy-
gote or compound heterozygote R501X
or 2282del4 mutations are leading to
disturbed skin barrier function. There-
fore FLG also appears to be an attrac-
tive candidate gene for the PSORS4
locus on chromosome 1q21 (Bowcock
et al., 1998; Capon et al., 1999).
To investigate the putative role of
FLG variants in psoriasis, we typed
each single-nucleotide polymorphism
in 360 patients with chronic plaque-
type psoriasis and 276 healthy control
individuals of Northern German origin.
Patients with psoriasis were recruited
by the department of dermatology
between 1998 and 2005 and the
diagnosis was established by standard
clinical criteria. The patients had a
median age of 44 years and a male:
female ratio of 0.7:1. The median age at
onset was 20 years. All control indivi-
duals were randomly selected from the
population of Northern Germany as
part of the PopGen project (Krawczak
et al., 2006) and had a male:female
ratio of 1:1.1. All patients and control
individuals gave written informed con-
sent to participation in the study. The
experiments have been approved by the
local ethics committee and the study
adheres to the Declaration of Helsinki
Principles.
Genotyping of the R501X variant
was performed using the TaqMan alle-
lic discrimination method (Applied
Biosystems, Foster City, CA) as reported
by Palmer et al. (2006) Genotypes with
the 2282del4 variant were determined
by sizing a fluorescent-labelled PCR
fragment on an ABI3730 automated
sequencer (Applied Biosystems) as de-
scribed elsewhere. (Palmer et al., 2006)
Each marker was tested for Hardy–-
Weinberg equilibrium in the control
population by a w2-test, which revealed
no abnormalities.
We detected no association for any
of the FLG mutations with chronic
plaque-type psoriasis. The allele fre-
quencies for both variants in psoriasis
were 2.2 and 1.7%, respectivelyAbbreviations: AD, atopic dermatitis; FLG, filaggrin gene
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(Table 1). These rates were identical in
controls, which also compared well to
the figures reported for Scottish, Irish,
and Danish populations (Palmer et al.,
2006). In particular, the rate for homo-
zygous null carriers was not signifi-
cantly enhanced in either FLG variant
(Table 2). Although FLG variants have a
particular role in the epidermal barrier,
they seem not to confer an increased
risk for inflammatory disease in general.
The presence of common disease loci
shared among different diseases, for
example, AD, psoriasis, Crohn’s dis-
ease, or rheumatoid arthritis, has re-
peatedly led to the concept of genes
predisposing to common pathophysio-
logical pathways (Bowcock and Cook-
son, 2004). Some genes involved, for
example, located in the major histo-
compatibility complex region or
CARD15 may be of general importance
in chronic inflammatory disease. In
contrast, variants in FLG appear to be
more specific to the target organ, as
they are not found in inflammatory
bowel disease, ulcerative colitis, or
sarcoidosis (Ruether et al., 2006). It
has to be emphasized, however, that
common genetic loci in psoriasis and
AD do not necessarily imply the very
same genes be involved in both dis-
eases. It might well be that different
genes involved in epidermal differentia-
tion and function account for genetic
linkage with the epidermal differentia-
tion complex region. In addition, clin-
ical epidemiology has shown that
psoriasis and AD are rather exclusive
diseases than being associated (Hense-
ler and Christophers, 1995). In fact,
although FLG expression might be
diminished in the psoriatic plaque in
parallel to the loss of the granular layer,
it is normally expressed in the unin-
volved skin (Fischer et al., 2004) and
becomes reconstituted during healing
of the psoriatic plaque (van der Vleuten
et al., 1996) This suggests that the basic
FLG function as far as it is genetically
determined might be undisturbed, and
lesional loss of FLG expression may
rather be a reactive process. Never-
theless, as new FLG variants are being
determined, it remains possible that a
different variant not yet discovered
might play a role in psoriasis. In
addition, the epidermal differentiation
complex might still harbor a major gene
for psoriasis as the PSORS4 locus has
been repeatedly confirmed in indepen-
dent patient cohorts (Bowcock et al.,
1998; Capon et al., 2001; Giardina
et al., 2006).
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TO THE EDITOR
Epidermolysis bullosa constitutes a group
of phenotypically diverse genodermatoses
which manifest with blistering and ero-
sions of the skin and mucous membranes
(Fine et al., 2000). Recent advances in
epidermolysis bullosa research have al-
lowed the identification of mutations in
10 different genes, which account for the
clinical heterogeneity in epidermolysis
bullosa (Pulkkinen and Uitto, 1999).
Mutations in the plectin gene
(PLEC1) are generally thought to cause
Abbreviations: EBS, epidermolysis bullosa simplex; EBS-MD, epidermolysis bullosa simplex associated
with muscular dystrophy; EBS-PA, epidermolysis bullosa simplex associated with pyloric atresia;
PTC, premature termination codon
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